Severe clinical toxicity associated with analytically confirmed recreational use of 25I–NBOMe: case series

  title={Severe clinical toxicity associated with analytically confirmed recreational use of 25I–NBOMe: case series},
  author={Simon L Hill and Tom Doris and Shivaraj Gurung and Stephen Katebe and Alexander Lomas and Michael P. Dunn and Peter G. Blain and Simon H L Thomas},
  journal={Clinical Toxicology},
  pages={487 - 492}
Abstract Context. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is a N-methoxybenzyl-substituted phenethylamine with potent serotoninergic effects. We describe seven cases of analytically confirmed toxicity due to the recreational use of 25I-NBOMe in the United Kingdom. Case series. Seven patients, all young adult males, presented to hospitals in the northeast of England with clinical toxicity after recreational drug use in January 2013. Clinical features included… 

Case series: toxicity from 25B-NBOMe – a cluster of N-bomb cases

It is suggested that management should be supportive and focused on preventing further (self) harm from 25B-NBOMe, and high doses of benzodiazepines may be required to control agitation.

A case of fatal intoxication due to the new designer drug 25B-NBOMe

The first scientific case report of fatal intoxication with 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe) is presented, based on autopsy and toxicological analyses.

Seizures, Systemic Inflammatory Response, and Rhabdomyolysis Associated With Laboratory-Confirmed 2C-I and 25-I Exposure

A 17-year-old male teenager developed seizures after taking “2 strips of acid,” but he became apneic and was intubated, and this case highlights the significant toxicity seen with these compounds.

25I-NBOMe related death in Australia: a case report.

Fatal 251-NBOMe Intoxication: A New Recreational Risk

A 17-year-old girl with mood disorders who died following 251-NBOMe ingestion is reported, revealing its lethality and suggesting that the patient died from fulminant serotonin syndrome following acute 251- NBOMe intoxication with a possible contribution from chronic lithium therapy.

NBOMe hallucinogenic drug exposures reported to the Danish Poison Information Centre.

A steep and sudden rise in reported NBOMe exposures in Denmark within 3-4 years is shown, and the results suggest that the use has started to decline.

Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus

This is a unique case of an analytically confirmed, accidental ingestion of 25I-NBOMe in a drug naïve adult, and the finding of 2C-I in the serum sample 50 minutes after intake indicates a fast metabolic breakdown of25I- NBOMe due to first-pass metabolism.

Designer drugs 2015: assessment and management

Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints, and long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.



A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug

A case of self-reported exposure to 25-I (25I-NBOMe), a novel phenethylamine derivative, with subsequent quantification in serum is described, a potent new synthetic drug with apparent significant behavioral toxicity that can be detected and quantified in serum.

Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET

11C-CIMBI-5 is a promising tool for investigation of 5-HT2A agonist binding in the living human brain and has a sufficient target-to-background ratio for future clinical use and is displaceable by ketanserin in both rats and pigs.

Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists

This study is the first to identify a hitherto unrecognized role for residue 6.51 in agonist activation of a serotonin G protein-coupled receptor (GPCR), whereas most previous reports have suggested a varied and sometimes contradictory role in homologous GPCRs.

25-I, a novel substituted amphetamine

  • Clin Toxicol
  • 2012

Case series of 25I-NBOMe 8. exposures with laboratory confi rmation

    Synthese und Pharmakologie potenter 5-HT2A-Rezeptorag-1. onisten mit N-2-Methoxybenzyl-Partialstruktur . Dissertation

      Severe poisoning 7. following self-reported use of 25-I, a novel substituted amphetamine